New Drug Approvals 2022
The following drugs have recently been approved by the FDA.
Tecvayli (teclistamab-cqyv) Injection
Date of Approval: October 25, 2022
Treatment for: Multiple Myeloma
Tecvayli (teclistamab-cqyv) is a bispecific B-cell maturation antigen (BCMA)-directed CD3 T-cell engager indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent and an anti-CD38 monoclonal antibody.
Imjudo (tremelimumab-actl) Injection
Date of Approval: October 21, 2022
Treatment for: Hepatocellular Carcinoma
Imjudo (tremelimumab-actl) is a cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) blocking antibody indicated in combination with durvalumab (Imfinzi) for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC).
Furoscix (furosemide) Injection
Date of Approval: October 7, 2022
Treatment for: Heart Failure
Furoscix (furosemide) is a loop diuretic indicated for the at-home treatment of congestion due to fluid overload in adults with NYHA Class II/III chronic heart failure.
Suggested readings:
About Author
